CVM

CEL-SCI Corporation (CEL-SCI) - 10-Q Summary

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for the period ended December 31, 2010. CEL-SCI is a biotechnology company focused on the development of Multikine, an immunotherapeutic drug for cancer treatment. The company has not yet generated revenue from product sales and relies on capital raises and grants to fund operations. As of December 31, 2010, the company announced the commencement of the Phase III clinical trial for Multikine.

Key Financial Metrics

Revenue Composition: Revenue consisted entirely of grant and other income ($662,818), primarily from a $733,437 grant received under the Patient Protection and Affordable Care Act (PPACA). Rent income was $0 for the current period compared to $30,000 in the prior year.

Expenses: Total expenses were $4,978,852. Research and Development (R&D) expenses were $3,264,428, and General and Administrative (G&A) expenses were $1,573,277.

Material Changes vs. Prior Period

• Net Income to Net Loss: The company swung from a net income of $19.2 million in the prior year to a net loss of $6.3 million. The prior year's income was driven by a $23.3 million gain on derivative instruments, whereas the current period saw a $1.9 million loss on the same instruments due to fluctuations in the company's stock price.
• Revenue Increase: Revenue increased significantly due to the recognition of PPACA grant funds ($640,385 earned in the quarter), whereas the prior period had minimal revenue.
• Cash Position: Cash and cash equivalents decreased by approximately $5.7 million during the quarter. This decline was largely due to operating cash burn and approximately $2.1 million in prepayments for the Phase III clinical trial.
• Derivative Liabilities: Total derivative liabilities increased from $6.9 million to $8.8 million, reflecting the mark-to-market valuation of outstanding warrants.

Outlook, Risks, and Management Commentary

• Phase III Trial: The company commenced the Phase III clinical trial for Multikine in December 2010. The net cost to the company is estimated at $25–$26 million. Two partners have agreed to fund a portion of this trial.
• Liquidity: Management believes it has sufficient capital to support operations for more than the next twelve months. The company has an agreement with McNicoll Lewis & Vlak, LLC (MLV) to sell up to $30 million of common stock via an "at-the-market" offering.
• Risks: The company has no assurance it will successfully raise additional capital or obtain FDA approval for its products. Continued losses are expected until regulatory approval and commercial sales are achieved.
• Legal Proceedings: The filing references ongoing legal proceedings detailed in the annual 10-K report, which contributed to increased legal fees in G&A expenses.

Investor Verification Checklist

• Grant Utilization: Verify the timeline and conditions for the remaining PPACA grant funds to be collected in October 2011.
• Phase III Funding: Confirm the specific financial commitments of the two partners funding the Phase III trial to ensure the $25–$26 million cost estimate is fully covered.
• Derivative Liability Exposure: Monitor the fair value of outstanding warrants (Series K, A-E, N, etc.), as fluctuations in stock price directly impact net income/loss and total liabilities.
• Capital Raise Progress: Track the utilization of the $30 million MLV sales agreement to assess future liquidity runway.
• Related Party Loan: Review the terms of the $1.1 million loan from the President (Maximilian de Clara), including the 15% interest rate and conversion options.